FLT3-mutated AML: standards of care and ongoing investigation
Ly V. Do, Jessica J. Jorgensen, Kieran D. Sahasrabudhe · 2026
Read FLT3-mutated AML: standards of care and ongoing investigation by Ly V. Do, Jessica J. Jorgensen, Kieran D. Sahasrabudhe (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13554001.txt.
Description
Ly Do, Jessica Jorgensen, and Kieran Sahasrabudhe review care for a form of leukemia with a gene change called FLT3. Their 2026 paper covers acute myeloid leukemia, the most common acute leukemia in adults. The FLT3 change is common in this disease. It worsens survival and raises the chance of relapse.
Drugs that block FLT3 are joining care plans at a fast pace. The review walks through their role for patients who are newly diagnosed. It also covers use when the disease returns or does not respond. Key open studies are mapped as well. The paper gives clinicians a compact guide to a fast-moving field, where the set of options keeps growing.
Catalog record
| CREATOR | Ly V. Do, Jessica J. Jorgensen, Kieran D. Sahasrabudhe |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |